James Bayard Caress MD
Neuromuscular Medicine, Neurophysiology
Associate Professor, Neurology, Bowman Gray School of Medicine of Wake Forest Univ
Join to View Full Profile
131 Miller StWinston Salem, NC 27103
Phone+1 336-716-2309
Fax+1 336-713-8588
Dr. Caress is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1994 - 1996
Duke University HospitalResidency, Neurology, 1991 - 1994
George Washington UniversityInternship, Internal Medicine, 1990 - 1991- George Washington University School of Medicine and Health SciencesClass of 1990
Certifications & Licensure
NC State Medical License 1996 - 2025
American Board of Psychiatry and Neurology Neurology- American Board of Psychiatry and Neurology Clinical Neurophysiology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
Clinical Trials
- Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2013 Aug 01
- A Trial of Tocilizumab in ALS Subjects Start of enrollment: 2015 Nov 01
Publications & Presentations
PubMed
- Miller Fisher Syndrome With an Electrophysiologic Phenotype of Sensory Neuronopathy.James B Meiling, Nicholas J Miller, James B Caress
Journal of Clinical Neuromuscular Disease. 2025-03-01 - Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial., Jinsy Andrews, Sabrina Paganoni, Eric A Macklin, Lori B Chibnik
JAMA Neurology. 2025-02-17 - Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial., Jeremy M Shefner, Björn Oskarsson, Eric A Macklin, Lori B Chibnik
JAMA. 2025-02-17
Press Mentions
Dosing Begins in Phase 2a Study of ALZT-OP1a for Mild-to-Moderate ALSSeptember 16th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
